SHANGHAI FUDAN H YC-,10 (FDY) - Total Liabilities
Based on the latest financial reports, SHANGHAI FUDAN H YC-,10 (FDY) has total liabilities worth €261.02 Million EUR (≈ $305.15 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore FDY cash flow metrics to assess how effectively this company generates cash.
SHANGHAI FUDAN H YC-,10 - Total Liabilities Trend (2021–2024)
This chart illustrates how SHANGHAI FUDAN H YC-,10's total liabilities have evolved over time, based on quarterly financial data. Check FDY asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
SHANGHAI FUDAN H YC-,10 Competitors by Total Liabilities
The table below lists competitors of SHANGHAI FUDAN H YC-,10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Supergas Energy Ltd
TA:SPGE
|
Israel | ILA913.17 Million |
|
M.C.S. Steel Public Company Limited
BK:MCS
|
Thailand | ฿1.70 Billion |
|
Kbi Metal Co. Ltd
KQ:024840
|
Korea | ₩146.21 Billion |
|
Nano X Imaging Ltd
NASDAQ:NNOX
|
USA | $19.38 Million |
|
Globe Union Industrial Corp
TW:9934
|
Taiwan | NT$10.10 Billion |
|
Impact Develop
RO:IMP
|
Romania | RON308.18 Million |
|
Servotronics Inc
NYSE MKT:SVT
|
USA | $13.01 Million |
|
Advenica AB
ST:ADVE
|
Sweden | Skr82.12 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down SHANGHAI FUDAN H YC-,10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of SHANGHAI FUDAN H YC-,10.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SHANGHAI FUDAN H YC-,10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SHANGHAI FUDAN H YC-,10 (2021–2024)
The table below shows the annual total liabilities of SHANGHAI FUDAN H YC-,10 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €281.23 Million ≈ $328.78 Million |
-45.72% |
| 2023-12-31 | €518.12 Million ≈ $605.74 Million |
-28.34% |
| 2022-12-31 | €722.99 Million ≈ $845.25 Million |
+22.21% |
| 2021-12-31 | €591.58 Million ≈ $691.62 Million |
-- |
About SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more